Evidence map›Paper›PMID 40603894›Full record

ArticleScientific reports2025

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy.

Anastasia Goloudina, Fabien Le Chevalier, Pierre Authié, Sylvain Ciret, Kirill Nemirov, Ingrid Fert, Fanny Moncoq, Benjamin Vesin, Amandine Noirat, Catherine Blanc and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anastasia GoloudinaPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Fabien Le ChevalierPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Pierre AuthiéPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Sylvain CiretPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Kirill NemirovPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Ingrid FertPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Fanny MoncoqPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Benjamin VesinPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Amandine NoiratPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Catherine BlancPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Yu WeiPasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Pierre Charneau *Pasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.
Laleh Majlessi *Pasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France. laleh.majlessi@pasteur.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutated oncogenic Kirsten rat sarcoma virus (KRAS) antigen is expressed in a large variety of cancers, including pancreatic, colorectal, and pulmonary cancers. The oncogenic KRAS mutations cause malignancies and are usually ubiquitously expressed by all cells of a tumor. The KRAS amino acid substitutions at the positions 12 or 13 are among the most frequent mutations in human cancers. Here, we developed immuno-oncotherapeutic non-integrative lentiviral vectors encoding a segment encompassing KRAS

Indexed as

Colorectal NeoplasmsEpitopesGenetic VectorsImmunotherapyLentivirusLung NeoplasmsNeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMiceEpitopesKRAS protein, humanProto-Oncogene Proteins p21(ras)Cancer immunotherapyInhibition of tumor growthKRASG12DKRAS oncogenic mutationsLentiviral vectors

Identifiers

PMID40603894
PMCPMC12223123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.